Skip to main content
Journal cover image

Adjuvant therapy for pancreatic cancer: an evolving paradigm.

Publication ,  Journal Article
Zhu, AX; Clark, JW; Willett, CG
Published in: Surg Oncol Clin N Am
October 2004

Pancreatic cancer is the fourth leading cause of death in men and fifth in women in the United States. The median survival is 8 to 12 months for patients with locally advanced and unresectable disease and only 3 to 6 months for those with metastatic disease at presentation. Surgical resection offers the only potentially curative treatment. However, only 15% to 20% of patients present with tumors amenable to resection at initial diagnosis. Even for those who undergo resection, the prognosis remains poor. The 5-year survival following pancreaticoduodenectomy is only about 25% to 30% for node-negative tumors and 10% for node-positive tumors. Because of the dismal outcome for patients with resectable pancreatic cancer, adjuvant therapy has been administered in an attempt to improve the local control and overall survival. This review highlights historic and current perspectives of adjuvant therapy in resected pancreatic cancer.

Duke Scholars

Published In

Surg Oncol Clin N Am

DOI

ISSN

1055-3207

Publication Date

October 2004

Volume

13

Issue

4

Start / End Page

605 / viii

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Survival Analysis
  • Risk Assessment
  • Radiotherapy, Adjuvant
  • Radiotherapy Dosage
  • Prognosis
  • Pancreatic Neoplasms
  • Pancreatectomy
  • Oncology & Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zhu, A. X., Clark, J. W., & Willett, C. G. (2004). Adjuvant therapy for pancreatic cancer: an evolving paradigm. Surg Oncol Clin N Am, 13(4), 605–viii. https://doi.org/10.1016/j.soc.2004.06.003
Zhu, Andrew X., Jeffrey W. Clark, and Christopher G. Willett. “Adjuvant therapy for pancreatic cancer: an evolving paradigm.Surg Oncol Clin N Am 13, no. 4 (October 2004): 605–viii. https://doi.org/10.1016/j.soc.2004.06.003.
Zhu AX, Clark JW, Willett CG. Adjuvant therapy for pancreatic cancer: an evolving paradigm. Surg Oncol Clin N Am. 2004 Oct;13(4):605–viii.
Zhu, Andrew X., et al. “Adjuvant therapy for pancreatic cancer: an evolving paradigm.Surg Oncol Clin N Am, vol. 13, no. 4, Oct. 2004, pp. 605–viii. Pubmed, doi:10.1016/j.soc.2004.06.003.
Zhu AX, Clark JW, Willett CG. Adjuvant therapy for pancreatic cancer: an evolving paradigm. Surg Oncol Clin N Am. 2004 Oct;13(4):605–viii.
Journal cover image

Published In

Surg Oncol Clin N Am

DOI

ISSN

1055-3207

Publication Date

October 2004

Volume

13

Issue

4

Start / End Page

605 / viii

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Survival Analysis
  • Risk Assessment
  • Radiotherapy, Adjuvant
  • Radiotherapy Dosage
  • Prognosis
  • Pancreatic Neoplasms
  • Pancreatectomy
  • Oncology & Carcinogenesis